PMID- 11841407
OWN - NLM
STAT- MEDLINE
DCOM- 20020306
LR  - 20190705
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 116
IP  - 1
DP  - 2002 Jan
TI  - CD38 expression and secondary 17p deletion are important prognostic factors in 
      chronic lymphocytic leukaemia.
PG  - 142-50
AB  - CD38 expression and chromosomal abnormalities are novel prognostic factors in 
      chronic lymphocytic leukaemia (CLL). However, their value remains undetermined. 
      CD38 was evaluated in 123 patients and chromosomal aberrations in 111 cases with 
      fluorescence in situ hybridization (FISH). CD38 expression was found in 27% of 
      the cases. In addition, seven out of 32 CD38- patients became CD38+ during 
      evolution of the disease. Chromosomal abnormalities included isolated 13q 
      deletion (40%), 12q trisomy (14%), 11q deletion (without 17p deletion) (14%) and 
      17p deletion (7%). CD38 expression was significantly associated with Binet stages 
      B and C, atypical morphology and 11q deletion. On univariate analysis of survival 
      estimates, advanced Binet stages, CD38+ phenotype, atypical morphology and 11q or 
      17p deletions were associated with shorter event-free survival (EFS), 
      treatment-free interval (TFI) and overall survival (OS). Multivariate analysis 
      identified both Binet stages and CD38 as independent prognostic factors with 
      regard to EFS and TFI. However, CD38 appeared as an independent factor for OS 
      when restricted to Binet stage A. Chromosomal aberrations were re-evaluated 
      during evolution in 31 cases. The 17p deletion was the most frequent new 
      chromosomal abnormality (35%) and significantly associated with death (64%). In 
      conclusion, CD38 expression and secondary 17p deletion are important poor 
      prognostic indicators, especially in Binet stage A CLL.
FAU - Chevallier, Patrice
AU  - Chevallier P
AD  - Laboratoire d'Hematologie, Institut de Biologie, Centre Hospitalier 
      Universitaire, Nantes, France.
FAU - Penther, Dominique
AU  - Penther D
FAU - Avet-Loiseau, Herve
AU  - Avet-Loiseau H
FAU - Robillard, Nelly
AU  - Robillard N
FAU - Ifrah, Norbert
AU  - Ifrah N
FAU - Mahe, Beatrice
AU  - Mahe B
FAU - Hamidou, Mohamed
AU  - Hamidou M
FAU - Maisonneuve, Herve
AU  - Maisonneuve H
FAU - Moreau, Philippe
AU  - Moreau P
FAU - Jardel, Henri
AU  - Jardel H
FAU - Harousseau, Jean Luc
AU  - Harousseau JL
FAU - Bataille, Regis
AU  - Bataille R
FAU - Garand, Richard
AU  - Garand R
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation)
RN  - 0 (Membrane Glycoproteins)
RN  - EC 3.2.2.5 (ADP-ribosyl Cyclase)
RN  - EC 3.2.2.5 (CD38 protein, human)
RN  - EC 3.2.2.5 (NAD+ Nucleosidase)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase
MH  - ADP-ribosyl Cyclase 1
MH  - Aged
MH  - *Antigens, CD
MH  - Antigens, Differentiation/*immunology
MH  - *Chromosome Aberrations
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Deletion
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*genetics/*immunology/mortality
MH  - Male
MH  - Membrane Glycoproteins
MH  - Middle Aged
MH  - NAD+ Nucleosidase/*immunology
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2002/02/14 10:00
MHDA- 2002/03/07 10:01
CRDT- 2002/02/14 10:00
PHST- 2002/02/14 10:00 [pubmed]
PHST- 2002/03/07 10:01 [medline]
PHST- 2002/02/14 10:00 [entrez]
AID - 3205 [pii]
AID - 10.1046/j.0007-1048.2001.3205.x [doi]
PST - ppublish
SO  - Br J Haematol. 2002 Jan;116(1):142-50. doi: 10.1046/j.0007-1048.2001.3205.x.